HIGHLANDS RANCH   Colorado, July 7, 2021 Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ:VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (OSA), today announced that the Company has unveiled new data from an independent patient survey…

HIGHLANDS RANCH   Colorado, May 26, 2021 HIGHLANDS RANCH, Colo., May 26, 2021 – Vivos Therapeutics, Inc. (“the Company”) (NASDAQ: VVOS), HIGHLANDS RANCH, Colo., May 26, 2021 – Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ:VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered…

Management to Host Conference Call Today at 5:00 pm ET HIGHLANDS RANCH Colorado, May 17, 2021 HIGHLANDS RANCH, Colo., May 17, 2021 – Vivos Therapeutics, Inc. (“the Company”) (NASDAQ: VVOS), HIGHLANDS RANCH, Colo., May 17, 2021 – Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ:VVOS), a medical technology company focused on developing and commercializing innovative…

Call Scheduled for Monday, May 17, 2021 at 5:00 pm ET HIGHLANDS RANCH   Colorado, March 13, 2021 HIGHLANDS RANCH, Colo., March 13, 2021 – Vivos Therapeutics, Inc. (“the Company”) (NASDAQ: VVOS), a a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate…

HIGHLANDS RANCH   Colorado, May 11, 2021 Vivos Therapeutics, Inc. (“the Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (OSA), today announced the closing of its underwritten follow-on public offering of 4,600,000 shares of its…

HIGHLANDS RANCH Colorado, April 14, 2021 Vivos Therapeutics, Inc. (“the Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (OSA), today announced the appointment of Mimi Guarneri, MD, FACC as an independent consultant serving in the role of Medical…

Vivos management to present at 9:00 am EDT on April 14, 2021 HIGHLANDS RANCH Colorado, April 12, 2021 Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (OSA), today announced that Kirk Huntsman, Chief…

Vivos to offer MyoCorrect via telemedicine for all Vivos-trained clinicians to use as therapeutic protocol in tandem with the Vivos System HIGHLANDS RANCH   Colorado, March 22, 2021 Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive…

Full Year Revenue Increase of 15% Management to Host Conference Call Today at 5:00 pm ET HIGHLANDS RANCH   Colorado, March 22, 2021 Vivos Therapeutics, Inc. (“Vivos” or “the Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (OSA), today reported…

Vivos management to present at 11:40 am Eastern Time on March 25, 2021 Colorado, September 23, 2021 HIGHLANDS RANCH, Colo., January 29, 2021 – Vivos Therapeutics, Inc. (“the Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (OSA), today…